Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Revenue grew 22.3% YoY
Concerns1
- Low interest coverage ratio of 0.1x
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ400.00 Cr | β | βΉ-10.00 | β | β | -0.2% | 22.3% | -86.8% |
| Mar 2024 | βΉ327.00 Cr | β | βΉ-76.00 | β | β | -1.9% | -18.9% | 28.8% |
| Mar 2023 | βΉ403.00 Cr | β | βΉ-59.00 | β | β | -1.4% | 31.3% | 84.4% |
| Mar 2022 | βΉ307.00 Cr | β | βΉ-32.00 | β | β | -0.8% | 53.5% | -86.3% |
| Mar 2021 | βΉ200.00 Cr | β | βΉ-233.00 | β | β | -5.0% | -65.6% | -697.4% |
| Mar 2020 | βΉ581.00 Cr | β | βΉ39.00 Cr | β | β | 0.8% | 5.8% | -30.4% |
| Mar 2019 | βΉ549.00 Cr | β | βΉ56.00 Cr | β | β | 1.1% | 15.8% | 51.4% |
| Mar 2018 | βΉ474.00 Cr | β | βΉ37.00 Cr | β | β | 0.8% | 5.1% | 54.2% |
| Mar 2017 | βΉ451.00 Cr | β | βΉ24.00 Cr | β | β | 0.5% | 6342.9% | 2300.0% |
| Mar 2016 | βΉ7.00 Cr | β | βΉ1.00 Cr | β | β | 2000.0% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 326 |
| Total Expenses | 275 |
| EBIT / Operating Profit | 51 |
| OPM % | 16% |
| Other Income | 46 |
| Finance Costs | 80 |
| Depreciation & Amortisation | 65 |
| Profit Before Tax | -47 |
| Tax % | - |
| Net Profit / PAT | -32 |
| EPS (βΉ) | -2.02 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Limitedthis co. | βΉ4.13 K Cr | βΉ400.00 Cr | 0.00 | 1.04 | 67.47 | 22.3% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |